VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q37837068 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000153.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q37837068‏
024 ‎‡a 0000-0002-3426-2274‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q37837068‏
100 0 ‎‡a Pedro R Cutillas‏ ‎‡c investigador‏ ‎‡9 ast‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Pedro R Cutillas‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Pedro R Cutillas‏ ‎‡c investigador‏ ‎‡9 es‏
400 0 ‎‡a Pedro R. Cutillas‏ ‎‡c ricercatore‏ ‎‡9 it‏
400 0 ‎‡a Pedro R Cutillas‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans‏
670 ‎‡a Author's Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence‏
670 ‎‡a Author's Application of proteomic techniques to the study of urine and renal tissue‏
670 ‎‡a Author's Cancer associated fibroblast FAK regulates malignant cell metabolism‏
670 ‎‡a Author's Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1.‏
670 ‎‡a Author's Characterization of a TiO₂ enrichment method for label-free quantitative phosphoproteomics.‏
670 ‎‡a Author's Clinical urinary peptidomics: learning to walk before we can run.‏
670 ‎‡a Author's Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome‏
670 ‎‡a Author's Current challenges in software solutions for mass spectrometry-based quantitative proteomics‏
670 ‎‡a Author's Disulfide-activated protein kinase G Iα regulates cardiac diastolic relaxation and fine-tunes the Frank-Starling response.‏
670 ‎‡a Author's Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs‏
670 ‎‡a Author's Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration‏
670 ‎‡a Author's Empirical inference of circuitry and plasticity in a kinase signaling network‏
670 ‎‡a Author's Erratum: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype‏
670 ‎‡a Author's Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.‏
670 ‎‡a Author's Global profiling of protein kinase activities in cancer cells by mass spectrometry‏
670 ‎‡a Author's Increased confidence in large-scale phosphoproteomics data by complementary mass spectrometric techniques and matching of phosphopeptide data sets‏
670 ‎‡a Author's Integrating phosphoproteome and transcriptome reveals new determinants of macrophage multinucleation‏
670 ‎‡a Author's Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.‏
670 ‎‡a Author's Large-scale models of signal propagation in human cells derived from discovery phosphoproteomic data‏
670 ‎‡a Author's mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype‏
670 ‎‡a Author's Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.‏
670 ‎‡a Author's Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors‏
670 ‎‡a Author's Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth‏
670 ‎‡a Author's Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.‏
670 ‎‡a Author's Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring‏
670 ‎‡a Author's Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage‏
670 ‎‡a Author's The MAP kinase pathway coordinates crossover designation with disassembly of synaptonemal complex proteins during meiosis‏
670 ‎‡a Author's The urinary proteome and metabonome differ from normal in adults with mitochondrial disease‏
670 ‎‡a Author's Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation‏
670 ‎‡a Author's Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry‏
670 ‎‡a Author's Withanolide Metabolites Inhibit PI3K/AKT and MAPK Pro-Survival Pathways and Induce Apoptosis in Acute Myeloid Leukemia Cells‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/DNB|1207399035‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/viaf/5662158631004823370001‏
909 ‎‡a (orcid) 0000000234262274‏ ‎‡9 1‏
919 ‎‡a characterisationofpreproendothelin1derivedpeptidesidentifiesendothelinlikedomainpeptideasamodulatorofendothelin1‏ ‎‡A Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1.‏ ‎‡9 1‏
919 ‎‡a clinicalurinarypeptidomicslearningtowalkbeforewecanrun‏ ‎‡A Clinical urinary peptidomics: learning to walk before we can run.‏ ‎‡9 1‏
919 ‎‡a combinedproteomicandmetabonomicstudiesin3geneticformsoftherenalfanconisyndrome‏ ‎‡A Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome‏ ‎‡9 1‏
919 ‎‡a currentchallengesinsoftwaresolutionsformassspectrometrybasedquantitativeproteomics‏ ‎‡A Current challenges in software solutions for mass spectrometry-based quantitative proteomics‏ ‎‡9 1‏
919 ‎‡a disulfideactivatedproteinkinasegiαregulatescardiacdiastolicrelaxationandfinetunesthefrankstarlingresponse‏ ‎‡A Disulfide-activated protein kinase G Iα regulates cardiac diastolic relaxation and fine-tunes the Frank-Starling response.‏ ‎‡9 1‏
919 ‎‡a drugrankingusingmachinelearningsystematicallypredictstheefficacyofanticancerdrugs‏ ‎‡A Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs‏ ‎‡9 1‏
919 ‎‡a dynamictraffickingandturnoverofjam100isessentialforendothelialcellmigration‏ ‎‡A Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration‏ ‎‡9 1‏
919 ‎‡a empiricalinferenceofcircuitryandplasticityinakinasesignalingnetwork‏ ‎‡A Empirical inference of circuitry and plasticity in a kinase signaling network‏ ‎‡9 1‏
919 ‎‡a erratummtorregulatesmapkapk2translationtocontrolthesenescenceassociatedsecretoryphenotype‏ ‎‡A Erratum: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype‏ ‎‡9 1‏
919 ‎‡a geneactivationofcebpausingsarnapreclinicalstudiesofthe1inhumansarnadrugcandidateforlivercancer‏ ‎‡A Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.‏ ‎‡9 1‏
919 ‎‡a globalprofilingofproteinkinaseactivitiesincancercellsbymassspectrometry‏ ‎‡A Global profiling of protein kinase activities in cancer cells by mass spectrometry‏ ‎‡9 1‏
919 ‎‡a increasedconfidenceinlargescalephosphoproteomicsdatabycomplementarymassspectrometrictechniquesandmatchingofphosphopeptidedatasets‏ ‎‡A Increased confidence in large-scale phosphoproteomics data by complementary mass spectrometric techniques and matching of phosphopeptide data sets‏ ‎‡9 1‏
919 ‎‡a integratingphosphoproteomeandtranscriptomerevealsnewdeterminantsofmacrophagemultinucleation‏ ‎‡A Integrating phosphoproteome and transcriptome reveals new determinants of macrophage multinucleation‏ ‎‡9 1‏
919 ‎‡a kinasesubstrateenrichmentanalysisprovidesinsightsintotheheterogeneityofsignalingpathwayactivationinleukemiacells‏ ‎‡A Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.‏ ‎‡9 1‏
919 ‎‡a largescalemodelsofsignalpropagationinhumancellsderivedfromdiscoveryphosphoproteomicdata‏ ‎‡A Large-scale models of signal propagation in human cells derived from discovery phosphoproteomic data‏ ‎‡9 1‏
919 ‎‡a mtorregulatesmapkapk2translationtocontrolthesenescenceassociatedsecretoryphenotype‏ ‎‡A mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype‏ ‎‡9 1‏
919 ‎‡a phosphoproteomicanalysisofleukemiacellsunderbasalanddrugtreatedconditionsidentifiesmarkersofkinasepathwayactivationandmechanismsofresistance‏ ‎‡A Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.‏ ‎‡9 1‏
919 ‎‡a phosphoproteomicsdataclassifyhematologicalcancercelllinesaccordingtotumortypeandsensitivitytokinaseinhibitors‏ ‎‡A Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors‏ ‎‡9 1‏
919 ‎‡a polyamineproductionisdownstreamandupstreamofoncogenicpi3ksignallingandcontributestotumourcellgrowth‏ ‎‡A Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth‏ ‎‡9 1‏
919 ‎‡a proteomicandgenomicintegrationidentifieskinaseanddifferentiationdeterminantsofkinaseinhibitorsensitivityinleukemiacells‏ ‎‡A Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.‏ ‎‡9 1‏
919 ‎‡a reconstructingkinasenetworktopologiesfromphosphoproteomicsdatarevealscancerassociatedrewiring‏ ‎‡A Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring‏ ‎‡9 1‏
919 ‎‡a reducedrenalmethylargininemetabolismprotectsagainstprogressivekidneydamage‏ ‎‡A Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage‏ ‎‡9 1‏
919 ‎‡a mapkinasepathwaycoordinatescrossoverdesignationwithdisassemblyofsynaptonemalcomplexproteinsduringmeiosis‏ ‎‡A The MAP kinase pathway coordinates crossover designation with disassembly of synaptonemal complex proteins during meiosis‏ ‎‡9 1‏
919 ‎‡a urinaryproteomeandmetabonomedifferfromnormalinadultswithmitochondrialdisease‏ ‎‡A The urinary proteome and metabonome differ from normal in adults with mitochondrial disease‏ ‎‡9 1‏
919 ‎‡a transitiontonaivehumanpluripotencymirrorspancancerdnahypermethylation‏ ‎‡A Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation‏ ‎‡9 1‏
919 ‎‡a ultrasensitiveandabsolutequantificationofthephosphoinositide3kinaseaktsignaltransductionpathwaybymassspectrometry‏ ‎‡A Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry‏ ‎‡9 1‏
919 ‎‡a withanolidemetabolitesinhibitpi3kaktandmapkprosurvivalpathwaysandinduceapoptosisinacutemyeloidleukemiacells‏ ‎‡A Withanolide Metabolites Inhibit PI3K/AKT and MAPK Pro-Survival Pathways and Induce Apoptosis in Acute Myeloid Leukemia Cells‏ ‎‡9 1‏
919 ‎‡a characterizationofatio2enrichmentmethodforlabelfreequantitativephosphoproteomics‏ ‎‡A Characterization of a TiO₂ enrichment method for label-free quantitative phosphoproteomics.‏ ‎‡9 1‏
919 ‎‡a applicationofproteomictechniquestothestudyofurineandrenaltissue‏ ‎‡A Application of proteomic techniques to the study of urine and renal tissue‏ ‎‡9 1‏
919 ‎‡a adipocytesdisruptthetranslationalprogrammeofacutelymphoblasticleukaemiatofavourtumoursurvivalandpersistence‏ ‎‡A Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence‏ ‎‡9 1‏
919 ‎‡a activatingmutationsinbrafdisruptthehypothalamopituitaryaxisleadingtohypopituitarisminmiceandhumans‏ ‎‡A Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans‏ ‎‡9 1‏
919 ‎‡a cancerassociatedfibroblastfakregulatesmalignantcellmetabolism‏ ‎‡A Cancer associated fibroblast FAK regulates malignant cell metabolism‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 LC|nb2007004397‏
996 ‎‡2 ISNI|0000000105756008‏
996 ‎‡2 SUDOC|242742114‏
996 ‎‡2 DNB|133351335‏
996 ‎‡2 LC|nb2010024856‏
996 ‎‡2 ISNI|0000000115737476‏
996 ‎‡2 BNCHL|10000000000000000244567‏
996 ‎‡2 PTBNP|1307073‏
996 ‎‡2 NUKAT|n 2009115391‏
996 ‎‡2 BNC|981058523966406706‏
996 ‎‡2 ISNI|0000000479073236‏
996 ‎‡2 J9U|987007454243505171‏
996 ‎‡2 BNF|17848681‏
996 ‎‡2 BAV|495_51925‏
996 ‎‡2 BNE|XX877758‏
996 ‎‡2 SUDOC|111125359‏
996 ‎‡2 BIBSYS|11024607‏
996 ‎‡2 BNF|15543325‏
996 ‎‡2 SUDOC|148359477‏
996 ‎‡2 LC|no2019060903‏
996 ‎‡2 BLBNB|000457699‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Cutillas, Pedro‏ ‎‡2 DNB|1207399035‏ ‎‡3 suggested‏ ‎‡3 standard number‏